ÐÂÎÅÖÐÐÄ

ÓÑÇéÁ´½Ó

ÄúµÄµ±Ç°Î»ÖãºÊ×Ò³ > ¹«Ë¾ÐÂÎÅ

¡¾Ò½Ñ§Ç°ÑØ¡¿ÁøÒ¶µ¶È¨Íþ·¢ÎÄ£¬ÖÐÃÀйÚÊÔ¼ÁPK£¬ÖйúÍêʤ£¡

·¢²¼Ê±¼ä£º2020-8-6

½üÆÚÓ¢¹ú¿ªÕ¹Á˹ØÓÚʹÓÃѪÇåѧ·½·¨¼ì²âÒ½»¤ÈËԱйڲ¡¶¾¸ÐȾµÄ´ó¹æÄ£ÊµÑé¡£¸ÃʵÑéÓɻʼҷÀÓùÖÐÐÄ·ÀÓù²¡ÀíѧÖÐÐÄ£¬Ó¢¹ú²®Ã÷º²ÒÁÀöɯ°×Å®ÍõҽԺҽѧ²¿¡¢ÇжûÎ÷ºÍÍþ˹ÃôÌØÒ½Ôº»ù½ð¡¢Î÷±±Â׶ز¡ÀíѧԺ¡¢Â׶ص۹úÀí¹¤Ñ§Ôº¡¢Ó¢¹ú¹úÁ¢Ñо¿ÔºÓëÒ½ÁƱ£½¡Ïà¹ØµÄ¸ÐȾºÍ¿¹¾úËØÄÍÒ©½¡¿µ±£»¤Ñо¿ÖÐÐÄ¡¢Ó¢¹úÂ×¶Ø´ó°ÂÃɵ½ֶùͯҽԺ¼ìÑé¿ÆºÍ¼ìÑéҽѧϵµÈÁªºÏ²ÎÓ룬²¢ÇÒ½øÐÐÁËÁ½¸ö½×¶Î£¬Ò»¹²6840ÀýµÄÁÙ´²ÊµÑé¡£

ʵÑéÖÐʹÓõļì²âÊÔ¼Á·Ö±ðÓÐÀ´×ÔÓÚÖйúÖ麣ÊÐҽѧ¹¤³Ì¹É·ÝÓÐÏÞ¹«Ë¾µÄSARS-COV-2 IGG/IGM ¼ì²âÊÔ¼ÁºÐ¡¢ÃÀ¹úCTKÉúÎï¼¼ÊõµÄCOVID-19 IGG/IGM ¼ì²âÊÔ¼ÁºÐ¡¢ÃÀ¹úEpitopeÕï¶ÏµÄCOVID-19 IGG ÃâÒß·¢¹âÊÔ¼ÁºÐ¡¢ÃÀ¹úÑÅÅ໯ѧ·¢¹âÊÔ¼Á¡£

ʵÑé½á¹ûÏÔʾ£¬ÖйúÖ麣ÊÐÒø¿ÆÒ½Ñ§¹¤³Ì¹É·ÝÓÐÏÞ¹«Ë¾µÄSARS-COV-2 IGG/IGM¼ì²âÊÔ¼ÁºÐ±íÏÖÍ»³ö£¬¼ì²âÁéÃô¶È´ïµ½93.4%£¬¼ì²âÌØÒìÐÔ´ïµ½99%£¬³¬Ô½ÃÀ¹úFDA UA¶Ôйڿ¹Ìå¼ì²âÊÔ¼ÁºÐµÄÐÔÄÜÖ¸±êÒªÇó£¨FDA UAµÄ±ê×¼£º¼ì²âÁéÃô¶È¡Ý90%£¬¼ì²âÌØÒìÐÔ¡Ý95%£©¡£

 

ÁøÒ¶µ¶ÔÓÖ¾£¨Lancet Respira Med 2020£©Õë¶Ô¸ÃʵÑ飬ÓÚ2020Äê7ÔÂ24ÈÕ¿¯·¢ÁËÌâΪ¡¶Point-of-careserological assays for delayed SARS-CoV-2 case identification among health-careworkers in the UK: a prospective multicentre cohort study¡·µÄÎÄÕ¡£

Ô­ÎÄÏÂÔØ£º/ÁøÒ¶µ¶¡¶Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study¡·.pdf

ÁøÒ¶µ¶LancetÊÇ1823Ä갮˼Ψ¶û(Elsevier)³ö°æ¹«Ë¾³ö°æµÄÊÀ½çȨÍþҽѧÔÓÖ¾£¬×ܲ¿Î»ÓÚÂ×¶Ø¡£ËûÒÔÍâ¿ÆÊÖÊõµ¶"ÁøÒ¶µ¶"(Lancet)µÄÃû³ÆÀ´ÎªÕâ·Ý¿¯ÎïÃüÃû£¬¶ø"Lancet"ÔÚÓ¢ÓïÖÐÒ²ÊÇ"¼â¶¥ñ·´°"µÄÒâ˼£¬½è´ËÔ¢Òâ×ÅÆÚ¿¯Á¢Ö¾³ÉΪ"ÕÕÁÁÒ½½çµÄÃ÷´°"(to let in light)¡£

 

ÁøÒ¶µ¶LancetʼÖÕÔÚÒ»Ð©ÖØ´óµÄҽѧÒéÌâÉÏÒÔÖ±ÑÔ¸Ò˵ÎÅÃû£¬¶øÆäÖ±ÑÔÎÞ»äµÄÀý×ÓÈç:ÅúÆÀÊÀ½çÎÀÉú×éÖ¯¡¢¾Ü¾øÈÃË³ÊÆÁÆ·¨µÄ¹¦Ð§Õýʽ³ÉΪÖÚ¶àÖÎÁÆ·¨Ñ¡ÔñÖеÄÒ»ÖÖ¡¢·¢±í2003ÄêÃÀÒÁÕ½ÕùƽÃñÉËÍöµÄͳ¼Æ¡¢¼°²»ÔÞ³ÉÀîµÂ¡¤°¬Ë¹Î¬¶û(Reed Elsevier)¼¯ÍÅÓë¾üÐè²úÒµ(Arms industry)ÓÐËù¹ØÁªµÈ¡£

±¾Õ¾µ¼º½ | Á˽âвúÆ· | ´ÙÏúÐÅÏ¢ | Òþ˽Õþ²ß | ʹÓÃÌõ¿î | ÁªÏµÎÒÃÇ

°æÈ¨ËùÓÐ 2006 - 2015 Ö麣ÊÐÒø¿ÆÒ½Ñ§¹¤³Ì¹É·ÝÓÐÏÞ¹«Ë¾ ±¸°¸ºÅ£ºÔÁICP±¸05105823ºÅ

  ¼¼ÊõÖ§³Ö£ºÖ麣Ìì»ÝÍøÂç
ÖÐÎÄ×ÖĻ˿ÍàµÚ1Ò³_×ÛºÏÉ«ÇøÑÇÖÞÊ츾ÁíÀà_ÎåÔÂÌìÔÚÏßÊÓÆµ¹ú²úÔÚÏß